Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.46 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602771 | 1.00 | SMYD3 (0.46) | SMYD3MLLT1KDRPARP1HPGD | |
| SCHEMBL3612356 | 1.00 | SMYD3 (0.46) | SMYD3MLLT1KDRPARP1HPGD | |
| SCHEMBL3613390 | 0.93 | MLLT1 (0.46) | MLLT1PARP1HPGDSMN1; SMN2PBK | |
| SCHEMBL3613385 | 0.93 | MLLT1 (0.46) | MLLT1PARP1HPGDSMN1; SMN2PBK | |
| Trifluoroacetic Acid SCHEMBL3610262 | 0.93 | SMYD3 (0.41) | SMYD3MLLT1KDRPARP1HPGD | |
| Trifluoroacetic Acid SCHEMBL3595470 | 0.93 | SMYD3 (0.41) | SMYD3MLLT1KDRPARP1HPGD | |
| SCHEMBL3603913 | 0.82 | ALOX15 (0.56) | SMYD3MLLT1KDRALOX15 | |
| SCHEMBL3603019 | 0.82 | ALOX15 (0.56) | SMYD3MLLT1KDRALOX15 | |
| SCHEMBL3599029 | 0.82 | DRD4 (0.52) | SMYD3MLLT1KDRPARP1PBK | |
| SCHEMBL3603024 | 0.82 | ALOX15 (0.56) | SMYD3MLLT1KDRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| WO-2009158375-A1 | AZA-CYLIC INDOLE- 2 -CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-30 | — | — | WO | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2009158375-A1 | AZA-CYLIC INDOLE- 2 -CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | SMYD3 811/4885MLLT1 2603/4885KDR 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.